Kevin Fernando, MBChB, MSc July 05, 2023 The advent of subcutaneously injectable GLP-1 receptor agonists for the management of type 2 diabetes during 2005 was arguably one of the greatest therapeutic advances for the condition since metformin. I was an early advocate of the class, given its potent glucose-lowering efficacy, secondary benefits of significant weight reduction, and...
Tag: <span>Oral GLP-1</span>
Post
New Oral GLP-1 Agonist for Obesity, Type 2 Diabetes
Miriam E. Tucker June 24, 2023 SAN DIEGO – Orforglipron, Eli Lilly’s investigational oral daily nonpeptide glucagon-like peptide-1 (GLP-1) agonist that can be taken with or without food, appears comparable with other injectable and oral agents in the class for treating obesity and type 2 diabetes, suggest two new phase 2 studies. Currently approved GLP-1 agonists for type...